Wednesday, October 22, 2014

Versar Changing the Environment: Brief Analyst Report by BrokerBank Securities, Inc. $VSR

      NEW YORK, Oct. 22, 2014 /PRNewswire/ -- Versar, Inc. (NYSEMKT: VSR) -
According to an August 2014 report by IBISWorld, the remediation and
environmental cleanup services industry in the United States is approximately
$18 billion, and has grown by 6.2% between 2009 and 2014.  The industry has
benefitted from recent natural disasters and industrial accidents that have
increased demand for the industry's services.  The remediation and environmental
cleanup services industry is relatively fragmented, with the four largest
players in the market controlling approximately 25% of industry revenues.  One
company involved in this industry is Versar, Inc.
      Versar, Inc. (NYSE: VSR) is a global project management company based in
the Washington, DC metropolitan area, with 23 locations around the world.  The
company provides technical and management support to federal, state, and local
government clients, as well as industrial clients, worldwide.  The company
offers construction management, environmental sciences and engineering
infrastructure solutions.  The company's solutions help clients to comply with
regulations, avoid liability, solve environmental problems, improve
infrastructure, and prevent pollution.  Versar has experience in commercial and
government engineering and environmental projects, including decontamination
cleanup of training ranges, airfields, and major buildings contaminated by PCBs
and other chemicals, and complex multidisciplinary site remediation.

iBio Expands Exclusive Product Collaboration With Novici Biotech $IBIO

      NEWARK, DE -- (Marketwired) -- 10/22/14 -- iBio, Inc. (NYSE MKT: IBIO), a
leading provider of plant-based biotechnology for developing and manufacturing
biological products, and Novici Biotech LLC (Novici) have agreed to broaden
their commercial collaboration, currently focused on antibodies and certain
vaccine products, to include iBio's proprietary IBIO-CFB03 product for
idiopathic pulmonary fibrosis, systemic sclerosis and other fibrotic diseases.
This expanded program will combine the strength of the iBioLaunch(TM) platform
with Novici's patented GRAMMR(R) technology for rapid evolution of gene
sequences to significantly increase expression yield of target proteins.
      IBIO-CFB03 and related proteins have been produced in plants on the
iBioLaunch platform substantially more quickly and cost-effectively than has
been possible with traditional methods. By combining the strengths of the
iBioLaunch platform with Novici's GRAMMR technology, iBio expects to drive
production efficiency even further as the fibrosis team initiates expanded
animal testing and additional IND-enabling tasks.

Sunday, September 21, 2014

Barron's Loves Yahoo! $BABA $GNW $BAC

$YHOO: Yahoo could have 35% upside, Barron's says
Sep 20 at 20:45

      Yahoo (YHOO) looks like the best way to play Alibaba $BABA and shares could have a 35% upside, Barron's contends in a follow up article.

GNW: Genworth shares could jump 80%, Barron's says
Sep 20 at 20:06
      Genworth deserves a price-to-book value closer to peers and shares could
be worth over $24, Barron's argues in a feature article.

$BAC: Bank of America could climb over 50%, Barron's says
Sep 20 at 19:48

      Bank of America could climb over 50% to around $25 in three years or
less, as the bank overcomes its problems, Barron's contends in a feature